NASDAQ: DMAC - DiaMedica Therapeutics Inc.

Yield per half year: +93.21%
Dividend yield: 0.00%
Sector: Healthcare

Share chart DiaMedica Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

more details
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2008-01-04
ISIN CA25253X2077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.diamedica.com
Цена ао 2.72
Change price per day: +1.31% (5.34)
Change price per week: -15.6% (6.41)
Change price per month: +3.84% (5.21)
Change price per 3 month: +29.43% (4.18)
Change price per half year: +93.21% (2.8)
Change price per year: +90.49% (2.84)
Change price per 3 year: +52.39% (3.55)
Change price per 5 year: +63.94% (3.3)
Change price per 10 year: 0% (5.41)
Change price per year to date: +22.12% (4.43)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.82 8
P/E 0 0
EV/EBITDA -4.18 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -35.78 0
ROE, % -37.96 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0188 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 1375.75 10
Yield Ebitda, % 80.45 9
Yield EPS, % -33 0
Total: 7.6
More

Institutions Volume Share, %
Cooperman, Leon G. 883623 2.33
Vanguard Group Inc 802171 2.11
Paragon Associates & Paragon Associates Ii Joint Venture 500000 1.32
Altium Capital Management, LP 287698 0.76
Bleichroeder LP 222317 0.59
Geode Capital Management, LLC 218778 0.58
Jacob Asset Management Of New York LLC 168730 0.44
Northern Trust Corporation 133633 0.35
Morgan Stanley 120995 0.32
First Manhattan Company 114744 0.3

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02526 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00098 27.77 1.68271



Head Job title Payment Year of birth
Mr. Dietrich John Pauls MBA President, CEO & Director 818.61k 1971 (54 years)
Mr. Scott Kellen CPA CFO & Corporate Secretary 485.43k 1965 (60 years)
Dr. Ambarish Shah Ph.D. Chief Technology Officer N/A
Mr. Dominic R. Cundari Chief Commercial Officer N/A 1951 (74 years)
Mr. David J. Wambeke Chief Business Officer N/A 1984 (41 year)
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer N/A 1961 (64 years)

Address: United States, Minneapolis. MN, 301 Carlson Parkway - open in Google maps, open in Yandex maps
Website: https://www.diamedica.com